AMVUTTRA®, Injektionslösung in einer Fertigspritze

7680690740016 CH-69074 Injektionslösung

Associated product:

AMVUTTRA sol inj ser pré 0.5 ml
AMVUTTRA®, Injektionslösung in einer Fertigspritze
AMVUTTRA®, Injektionslösung in einer Fertigspritze
AMVUTTRA®, Injektionslösung in einer Fertigspritze
1 / 3
google

Article details

Package size
1
Selling units
1
Measure
Fertigspritze(n)
Galenic form
Injektionslösung
Galenic group
Injektion/Infusion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
16/07/2025
Patient information leaflet
Français
16/07/2025
Patient information leaflet
Italien
16/07/2025
Summary of Product Characteristics
Allemand
16/07/2025
Summary of Product Characteristics
Français
16/07/2025
Summary of Product Characteristics
Italien
16/07/2025

Detailed composition

Substance Quantity Type Category
SUS
25.0 MG Substance Wirkstoff (Principe actif)
SUS
- Substance HNIDK
SUS
- Substance HNIDK
SUS
- Substance HNIDK
SUS
- Substance HNIDK
SUS
- Substance HNIDK
SUS
- Substance HNIDK
SUS
- Substance HBESI

Reimbursement information

Public price
CHF 89440.90
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/02/2024

Authorization holder

Alnylam Switzerland GmbH

6300 Zug

Authorization information

Swissmedic authorization number
69074
Drug name
AMVUTTRA®, Injektionslösung in einer Fertigspritze
Galenic form
INJFS
ATC Code
N07XX18
Authorization status
Z
Dispensing category
B
First authorization
23/06/2023
Authorization expiration date
22/06/2028
IT Number
01.99.0.
Domain
Human medicine
Field of application
Amvuttra wird zur Behandlung der hereditären Transthyretin-Amyloidose (hATTR-Amyloidose) bei erwachsenen Patienten mit Polyneuropathie der Stadien 1 oder 2 angewendet

Package details

Description (FR)
AMVUTTRA sol inj ser pré 0.5 ml
Description (DE)
AMVUTTRA Inj Lös Fertspr 0.5 ml
Market launch
23/06/2023
Narcotic (BTM)
No

Application methods

SUBC